Vasoneuronal coupling in migraineurs after subcutaneous sumatriptan: a TCD study.

Area of Science:

• Neuroscience
• Pharmacology
• Vascular Biology

Background:

• The trigeminovascular model explains migraine pain via neurogenic inflammation.
• Sumatriptan, a 5-HT1 agonist, targets meningeal artery vasoconstriction.
• Potential vasoconstrictive effects of sumatriptan on cerebral arteries remain unclear.

Purpose of the Study:

• To investigate sumatriptan's vasoactive effects on intracranial cerebral arteries.
• To assess potential changes in cerebral blood flow velocity (CBFV) and pulsatility index (PI) after sumatriptan administration.
• To evaluate the risk of cerebral ischemia associated with sumatriptan's cerebral circulation effects.

Main Methods:

• Studied 27 migraineurs measuring CBFV and PI in posterior cerebral arteries (PCAs).
• Monitored arterial blood pressure (BP), heart rate (HR), and respiration rate (RR).
• Assessed CBFV and PI changes before and 30 minutes after subcutaneous 6 mg sumatriptan, including response to visual stimulation.

Main Results:

• Despite a significant rise in diastolic blood pressure, mean CBFV remained constant.
• The relative increase in CBFV during visual stimulation did not change post-sumatriptan.
• No significant alterations in absolute mean CBFV or PI values were observed.

Conclusions:

• Sumatriptan does not appear to cause vasoconstriction in the human intracranial arterial circulation.
• The findings do not support the hypothesis that sumatriptan poses a risk of cerebral ischemia due to cerebral vasoconstriction.
• Sumatriptan's mechanism in migraine treatment likely does not involve significant cerebral arterial vasoactivity.